CN111000925A - External application Huojindan essential oil for treating soft tissue injury - Google Patents
External application Huojindan essential oil for treating soft tissue injury Download PDFInfo
- Publication number
- CN111000925A CN111000925A CN201911306164.6A CN201911306164A CN111000925A CN 111000925 A CN111000925 A CN 111000925A CN 201911306164 A CN201911306164 A CN 201911306164A CN 111000925 A CN111000925 A CN 111000925A
- Authority
- CN
- China
- Prior art keywords
- essential oil
- soft tissue
- tissue injury
- huojindan
- frankincense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 154
- 208000026137 Soft tissue injury Diseases 0.000 title claims abstract description 63
- 244000153955 Reynoutria sachalinensis Species 0.000 claims abstract description 18
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims abstract description 18
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 17
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 17
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 17
- 244000183685 Citrus aurantium Species 0.000 claims abstract description 17
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 17
- 239000004863 Frankincense Substances 0.000 claims abstract description 17
- 244000018716 Impatiens biflora Species 0.000 claims abstract description 17
- 235000015912 Impatiens biflora Nutrition 0.000 claims abstract description 17
- 235000005155 Tanacetum balsamita Nutrition 0.000 claims abstract description 17
- 241001546929 Campsis grandiflora Species 0.000 claims abstract description 14
- 240000005001 Paeonia suffruticosa Species 0.000 claims abstract description 14
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims abstract description 14
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 12
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 12
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 12
- 241001254604 Angelica pubescens Species 0.000 claims abstract description 12
- 241000723346 Cinnamomum camphora Species 0.000 claims abstract description 12
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940116229 borneol Drugs 0.000 claims abstract description 12
- 229930008380 camphor Natural products 0.000 claims abstract description 12
- 229960000846 camphor Drugs 0.000 claims abstract description 12
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 12
- 241000208296 Datura Species 0.000 claims abstract description 11
- 238000000605 extraction Methods 0.000 claims description 60
- 239000007788 liquid Substances 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 18
- 239000012530 fluid Substances 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 17
- 241000628997 Flos Species 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 26
- 241000700159 Rattus Species 0.000 description 40
- 238000000926 separation method Methods 0.000 description 29
- 230000000694 effects Effects 0.000 description 27
- 229940079593 drug Drugs 0.000 description 17
- 230000008961 swelling Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 208000014674 injury Diseases 0.000 description 15
- 230000006378 damage Effects 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 9
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 9
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 8
- 102000003777 Interleukin-1 beta Human genes 0.000 description 7
- 108090000193 Interleukin-1 beta Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000004087 circulation Effects 0.000 description 6
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 5
- 229960002986 dinoprostone Drugs 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 5
- 241001649190 Campsis Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 210000000281 joint capsule Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000009306 yunnan baiyao Substances 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 206010014080 Ecchymosis Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000011278 co-treatment Methods 0.000 description 2
- 230000001700 effect on tissue Effects 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 208000007356 Fracture Dislocation Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000007084 physiological dysfunction Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/02—Recovery or refining of essential oils from raw materials
- C11B9/025—Recovery by solvent extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Huojindan essential oil for treating soft tissue injury by external use, which can effectively solve the problem of medicament application for treating soft tissue injury and adopts the technical scheme that the Huojindan essential oil comprises the following components: 2-4mL of datura flower essential oil, 2-4mL of tree peony bark essential oil, 2-4mL of giant knotweed essential oil, 2-4mL of pubescent angelica root essential oil, 2-4mL of frankincense essential oil, 2-4mL of immature bitter orange essential oil, 1.5-2.5mL of campsis grandiflora essential oil, 1.5-2.5mL of garden balsam stem essential oil, 1.5-2.5g of borneol and 1.5-2.5g of camphor.
Description
Technical Field
The invention relates to medicine, in particular to Huojindan essential oil for treating soft tissue injury by external application.
Background
The soft tissue injury refers to the injury of tissues except bones below the skin of the human body, such as muscles, ligaments, fascia, tendons, synovium, fat, joint capsules, synovial capsules and the like, and different conditions of peripheral nerves and blood vessels, has no fracture or dislocation, takes local skin ecchymosis, swelling, pain, limb movement disorder and the like as main clinical manifestations, and is a common disease of the motion system. These tissues are affected by extrinsic and intrinsic different injurious factors, which can cause tissue destruction and damage due to tissue physiological dysfunction. The health of people is affected to different degrees, so how to treat soft tissue injury is a technical concern. The traditional Chinese medicine treatment is a special feature, although various medicines for treating soft tissue injury are available, the local part can be applied by cold compress within 24 hours of injury, and the treatment medicines comprise safflower oil, Yunnan white drug tincture, traumatic injury massage ointment and the like, but the use and the curative effect are not satisfactory due to various reasons, so the innovation of the medicine for treating soft tissue injury is a technical problem which is concerned and solved by the industry.
Disclosure of Invention
Aiming at the situation, in order to overcome the defects of the prior art, the invention aims to provide the Huojindan essential oil for treating soft tissue injury by external application, which can effectively solve the problem of medicament for treating soft tissue injury.
The technical scheme for solving the problem is that the Huojindan essential oil for treating soft tissue injury by external use comprises the following components: 2-4mL of datura flower essential oil, 2-4mL of tree peony bark essential oil, 2-4mL of giant knotweed essential oil, 2-4mL of pubescent angelica root essential oil, 2-4mL of frankincense essential oil, 2-4mL of immature bitter orange essential oil, 1.5-2.5mL of campsis grandiflora essential oil, 1.5-2.5mL of garden balsam stem essential oil, 1.5-2.5g of borneol and 1.5-2.5g of camphor, and uniformly mixing, wherein:
the flos Daturae Metelis essential oil is prepared by pulverizing flos Daturae Metelis into coarse powder passing through a 10-20 mesh sieve and supercritical CO2Extracting fluid, wherein the weight-volume ratio of liquid to material is 1: 10-20, the weight-volume ratio refers to that the solid is measured by g, the liquid is measured by mL (the same below), the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the flos daturae essential oil is obtained;
the essential oil of moutan bark is prepared by crushing moutan bark into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction, liquid material weight bodyThe volume ratio is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the tree peony bark essential oil is obtained;
the giant knotweed essential oil is prepared by crushing giant knotweed into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain giant knotweed essential oil;
the radix angelicae pubescentis essential oil is prepared by crushing radix angelicae pubescentis into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the pubescent angelica essential oil is obtained;
the frankincense essential oil is prepared by crushing frankincense, sieving with a 10-20-mesh sieve and performing supercritical CO2Fluid extraction is carried out, the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the frankincense essential oil;
the immature bitter orange essential oil is prepared by crushing immature bitter oranges into coarse powder which is sieved by a sieve with 10-20 meshes and subjected to supercritical CO treatment2Performing fluid extraction, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the immature bitter orange essential oil;
the campsis essential oil is prepared by crushing campsis grandiflora into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the campsis grandiflora essential oil is obtained;
the garden balsam stem essential oil is prepared by crushing garden balsam stems into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, and the separation temperature is 50-60 DEG CSeparating at 4.5-5.5 MPa for 1.5-2.5 h to obtain garden balsam stem essential oil;
the borneol and the camphor meet the requirements of national formulary.
In the formula, the tree peony bark has the effects of activating blood and dissipating blood stasis, the giant knotweed has the effects of activating blood and dissipating blood stasis and relieving pain, the trumpet creeper has the effects of activating blood and dissipating blood stasis, and detoxifying and reducing swelling, and the tree peony bark, the giant knotweed has the effects of activating blood and dissipating blood stasis and relieving pain, and the trumpet creeper has the effects. Datura flower has the effects of relieving pain and spasm, and is widely applied to various pain diseases such as traumatic injury and the like; the radix angelicae pubescentis is pungent, bitter and dry, good at dispelling wind-damp and relieving pain, and is used for treating arthralgia due to wind-cold-dampness on muscles and joints; the garden balsam stem is used as a ministerial drug for dispelling wind and eliminating dampness, and detoxifying and relieving pain, and treating traumatic injury and stasis and pain. The immature bitter orange is used for promoting the circulation of qi, the frankincense is used for promoting the circulation of blood and promoting the circulation of qi to relieve pain, the swelling is reduced and the tissue is generated, and the qi circulation is used for promoting the circulation of blood, so that the blood stasis is relieved and the blockage is removed. Borneol and camphor are added as auxiliary materials to relieve pain so as to assist the efficacy of the medicine. The medicines are combined to play the roles of activating blood circulation, dissipating blood stasis, promoting qi circulation, relieving swelling and alleviating pain.
The invention has the advantages of rich raw materials, simple preparation method, easy production and preparation, convenient use, good effect, safe medication, stable and reliable curative effect, is effectively used for treating soft tissue injury, is an innovation on the medicine for treating soft tissue injury, and has obvious economic and social benefits.
Detailed Description
The following examples are provided to explain the present invention in detail.
The invention may be embodied in the form of the following examples.
Example 1
In the specific implementation of the invention, the Huojindan essential oil for external use for treating soft tissue injury comprises the following components: 3mL of datura flower essential oil, 3mL of tree peony bark essential oil, 3mL of giant knotweed essential oil, 3mL of pubescent angelica root essential oil, 3mL of frankincense essential oil, 3mL of immature bitter orange essential oil, 2mL of campsis grandiflora essential oil, 2mL of garden balsam stem essential oil, 2g of borneol and 2g of camphor, and uniformly mixing to obtain the medicine, wherein:
the flos Daturae Metelis essential oil is prepared by pulverizing flos Daturae Metelis into coarse powder passing through a 10-20 mesh sieve and supercritical CO2Extracting with a fluid, wherein the weight-volume ratio of liquid to material is 1: 10-20, the weight-volume ratio refers to that the solid is counted by g, the liquid is counted by mL (the same below), the extraction temperature is 42-50 DEG CExtracting at 20-25 MPa, 50-60 ℃ and 4.5-5.5 MPa for 1.5-2.5 h to obtain flos Daturae Metelis essential oil;
the essential oil of moutan bark is prepared by crushing moutan bark into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Extracting the fluid, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the tree peony bark essential oil;
the giant knotweed essential oil is prepared by crushing giant knotweed into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain giant knotweed essential oil;
the radix angelicae pubescentis essential oil is prepared by crushing radix angelicae pubescentis into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the pubescent angelica essential oil is obtained;
the frankincense essential oil is prepared by crushing frankincense, sieving with a 10-20-mesh sieve and performing supercritical CO2Fluid extraction is carried out, the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the frankincense essential oil;
the immature bitter orange essential oil is prepared by crushing immature bitter oranges into coarse powder which is sieved by a sieve with 10-20 meshes and subjected to supercritical CO treatment2Performing fluid extraction, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the immature bitter orange essential oil;
the campsis essential oil is prepared by crushing campsis grandiflora into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction is carried out1.5-2.5 h to obtain the campsis grandiflora essential oil;
the garden balsam stem essential oil is prepared by crushing garden balsam stems into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the garden balsam stem essential oil is obtained;
the borneol and the camphor meet the requirements of national formulary.
Example 2
In the specific implementation of the invention, the Huojindan essential oil for external use for treating soft tissue injury comprises the following components: 2.5mL of datura flower essential oil, 3.5mL of tree peony bark essential oil, 2.5mL of giant knotweed essential oil, 3.5mL of pubescent angelica root essential oil, 2.5mL of frankincense essential oil, 3.5mL of immature bitter orange essential oil, 1.7mL of campsis grandiflora essential oil, 2.3mL of garden balsam stem essential oil, 1.7g of borneol and 2.3g of camphor, and the preparation method is the same as that of example 1.
Example 3
In the specific implementation of the invention, the Huojindan essential oil for external use for treating soft tissue injury comprises the following components: 3.5mL of datura flower essential oil, 2.5mL of tree peony bark essential oil, 3.5mL of giant knotweed essential oil, 2.5mL of pubescent angelica root essential oil, 3.5mL of frankincense essential oil, 2.5mL of immature bitter orange essential oil, 2.3mL of campsis grandiflora essential oil, 1.7mL of garden balsam stem essential oil, 2.3g of borneol and 1.7g of camphor, and the preparation method is the same as that of example 1.
The invention has scientific and reasonable compatibility, mutual support of components, safe medication, stable and reliable curative effect and very good experimental effect, is used for treating soft tissue injury, and has the following related data:
first, animal experiment
1 materials of the experiment
1.1 test drugs
The product of example 1 of the invention.
1.2 Experimental animals: wistar rats, male, 180-220 g, 130, certificate number: no. 37009200017327.
1.3 modeling and grouping: 120 male Wistar rats were selected, 24 non-model rats were randomly selected, and the rest rats were modeled. Model making machineFasting with 7% Na was prohibited 1 day before each experiment2S, depilating the hind limb after the solution is dissolved; after the chloral hydrate is anesthetized by intraperitoneal injection, a rat is fixed on a self-made impactor, a 20cm plastic tube with the diameter equivalent to that of a 200g weight impacts the thick muscle of the outer thigh of the rat from a 30cm vertical free falling body in the weight with the weight of 200g, the rat is continuously impacted for 3 times, the impact area is about 1 multiplied by 2cm, and a non-open soft tissue injury model is established. The hit part is observed 1h after the model is built, bleeding spots or ecchymosis (no damage to local skin) appear under the skin, local soft tissue swelling, palpation observation, no fracture and dislocation signs, and limb lameness after revival, if the conditions are met, the model building is successful. Selecting successfully molded rats, and randomly dividing the rats into a model group, a Yunnan Baiyao aerosol group and a large and small dose group of Huojindan essential oil, wherein each group comprises 24 rats.
1.4 detection index
① measuring swelling degree of soft tissue injury of rat on days 1, 4 and 7, respectively, and subtracting the healthy side volume from the affected side volume to obtain the difference between the two side volumes, which is swelling degree;
② measuring the temperature of the center of the impact molding area and the temperature of the opposite side along the two-side mark points on days 1, 4 and 7, recording, keeping the room temperature constant during measurement, maintaining the temperature at about 22 ℃ by an air conditioner, subtracting the skin temperature of the healthy side from the skin temperature of the affected side to obtain the difference value of the skin temperatures of the two sides, and performing statistical analysis by using the difference value of the skin temperatures;
③ the groups were obtained on days 1, 4 and 7 (8), and the levels of prostaglandin E2(PGE2) and tumor necrosis factor (TNF- α) in rat injured tissue homogenate and the levels of IL-1 β and fibroblast growth factor (bFGF) in serum were measured;
④ Each group was obtained on days 1, 4 and 7 (8), and HE staining of injured tissues was performed, and histopathological observation was performed.
PGE2, TNF- α, IL-1 β, and bFGF kit, Calvin Biotech, Suzhou, lot No. 20190104A.
2 statistical treatment
SPSS21.0 statistical software statistically processes the experimental results, and the average value plus or minus standard deviation is used for measuring data
The form of the expression shows that the comparison among groups adopts one-factor analysis of variance, the test of the uniform variance is carried out by an LSD method, the test of the non-uniform variance is carried out by a Games-Howell method, and the test of the grade data is carried out by Ridit.
3 results of the experiment
3.1 Effect on temperature difference of rat skin of Soft tissue injury model
Table 1: influence of Huohjindan essential oil on temperature difference of rat skin of soft tissue injury model (
n＝8)
Note: denotes the ratio to model group, P < 0.05; p <0.01 for the model group ratio
From table 1, it is known that: the skin temperature difference was significantly higher in the model group compared to the blank group on days 1, 4 and 7 (P < 0.01). Compared with the model group, on the 1 st day of administration, the group containing Yunnan Baiyao, 1-day essential oil and 1-day Huojindan essential oil can obviously reduce the skin temperature difference (P is less than 0.01) of the rat with the soft tissue injury model; on the 4 th day of administration, the skin temperature difference (P is less than 0.01) of the rats with the soft tissue injury model can be remarkably reduced by the Yunnan white drug group and the Huojindan essential oil large and small dose groups; on the 7 th day of administration, the Yunnan white drug powder group and the Huojindan essential oil large dose group can obviously reduce the skin temperature difference (P is less than 0.01) of the rat with the soft tissue injury model; the Huojindan essential oil small-dose group can obviously reduce the temperature difference (P <0.05) of the rat skin of the soft tissue injury model.
3.2 Effect on swelling degree of Soft tissue injury model rat
Table 2: influence of Huohuandan essential oil on swelling degree of soft tissue injury model rat (
n＝8)
Note: denotes the ratio to model group, P < 0.05; p <0.01 for the model group ratio
From table 2, it is known that: the model group showed significant swelling at the lesion sites on days 1, 4 and 7 (P <0.01) compared to the blank group. Compared with the model group, the Yunnan Baiyao can obviously reduce the swelling degree of the rats with soft tissue injury models on the 4 th and 7 th days (P is less than 0.01); the large and small dose groups of the Huojindan essential oil can obviously reduce the swelling degree of rats with soft tissue injury models on day 4 (P < 0.01); the large-dose group of the Huojindan essential oil can obviously reduce the swelling degree of a soft tissue injury model rat on the 7 th day (P <0.01), and the small-dose group of the Huojindan essential oil can obviously reduce the swelling degree of the soft tissue injury model rat on the 4 th day (P < 0.05).
3.3 Effect on tissue homogenates PGE2 and TNF- α at rat injury sites in the model of Soft tissue injury
3.3.1 Effect on Soft tissue injury model rat injury site tissue homogenate PGE2
Table 3: influence of Huojindan essential oil on tissue homogenate PGE2 at injured part of rat in soft tissue injury model (
n＝8)
Note: denotes the ratio to model group, P < 0.05; p <0.01 for the model group ratio
From table 3, it is known that: the model group had significantly elevated levels of tissue homogenate PGE 2(P <0.01) at injury sites on days 1, 4, and 7 compared to the blank group. Compared with the model group, on the 4 th day of administration, the Yunnan Baiyao and Huojindan essential oil can greatly reduce the level of PGE 2(P <0.01) of tissue homogenate at the injured part of a rat of a soft tissue injury model; on the 7 th day of administration, the Yunnan white drug powder group, the Huojindan essential oil big group and the Huojindan essential oil small dose group can obviously reduce the tissue homogenate PGE2 level (P <0.01) of the rat injury part of the soft tissue injury model.
3.3.1 Effect on tissue homogenate TNF- α at rat injury site in Soft tissue injury model
TABLE 4 Effect of Huojindan essential oil on tissue homogenate TNF- α at the injured part of rat in soft tissue injury model: (
n＝8)
Note: denotes the ratio to model group, P < 0.05; p <0.01 for the model group ratio
From Table 4, it is known that the tissue homogenate TNF- α level of the injury part of the model group is obviously increased (P <0.01) on the 1 st, 4 th and 7 th days compared with the blank group, the tissue homogenate TNF- α level (P <0.01) of the injury part of the rat of the soft tissue injury model can be obviously reduced by the large and small dose group of Yunnan white drug group and Huojindan essential oil on the 4 th day of administration, and the tissue homogenate TNF- α level (P <0.01) of the injury part of the rat of the soft tissue injury model can be obviously reduced by the large dose group of the Yunnan white drug group and Huojindan essential oil on the 7 th day of administration.
3.4 Effect on rat serum IL-1 β and bFGF in Soft tissue injury model
3.4.1 Effect on Soft tissue injury model rat serum IL-1 β
Table 5: influence of Huojindan essential oil on serum bFGF level of rat with soft tissue injury model: (
n＝8)
Note: denotes the ratio to model group, P < 0.05; p <0.01 for the model group ratio
Table 5 shows that compared with the blank group, the serum IL-1 β level of the model group is obviously increased (P <0.01) on the 1 st, 4 th and 7 th days, compared with the model group, the Yunnan white drug group and the Huojindan essential oil large and small dose group can obviously reduce the serum IL-1 β level (P <0.01) of the soft tissue injury model rat on the 4 th day of administration, and the Yunnan white drug group and the Huojindan essential oil large and small dose group can obviously reduce the serum IL-1 β level (P <0.01) of the soft tissue injury model rat on the 7 th day of administration.
3.4.2 Effect on serum bFGF levels in rats in Soft tissue injury model
Table 6: influence of Huojindan essential oil on serum bFGF level of rat with soft tissue injury model: (
n＝8)
Note: denotes the ratio to model group, P < 0.05; p <0.01 for the model group ratio
From table 5, it is known that: the serum bFGF levels were significantly elevated on days 1, 4 and 7 in the model group compared to the blank group (P < 0.01). Compared with the model group, on the 4 th day of administration, the Yunnan white drug group and the Huojindan essential oil with large and small dosage can obviously increase the serum bFGF level (P is less than 0.01) of the rat with the soft tissue injury model; the serum bFGF level (P <0.05) of the injury part of a rat with a soft tissue injury model can be obviously increased by the 7 th day of administration and the large and small dose groups of the Huojindan essential oil.
Second, clinical application
Under the condition of ensuring safety in animal experiments and clinical application, the effect is very good, and the related information is as follows (taking example 1 as an example):
soft tissue injury refers to acute injury of skin, subcutaneous tissue, fascia, muscle, blood vessel, nerve, ligament, joint capsule, synovial capsule, etc., has no fracture or dislocation, and is common disease of motor system with local skin ecchymosis, swelling, pain, limb movement disorder, etc. as main clinical symptoms.
15 patients with soft tissue injury diagnosed by an outpatient diagnosis, 10 men and 5 women, the age of 15-56 years and the course of disease of 30 min-70 h.
Diagnostic criteria: has history of acute trauma; pain, swelling, tenderness, and dysfunction of the corresponding parts of the limbs; no fracture dislocation; the disease course is within 72h (also called acute soft tissue injury).
The treatment scheme comprises the following steps: cleaning the skin of the affected part of a patient with confirmed soft tissue injury, and applying Huojindan essential oil to the soft tissue injury part at a concentration of 0.15mL/cm2Per treatment, 3 times/d, 7d for 1 treatment course, and the treatment effect is counted.
The evaluation standard of curative effect is as follows: and (3) healing: disappearance or remission > 90%; the effect is shown: the symptoms are obviously relieved, and the symptom relief is more than 70%; improvement: symptom relief > 30%; and (4) invalidation: compared with before treatment, the symptoms and signs are not obviously improved.
According to the treatment scheme, after 15 cases of diagnosed soft tissue injury patients are treated by adopting the essential oil, the results are as follows through statistical treatment: 15 patients with soft tissue injury are recovered for 11 cases (73.3%), have obvious effect for 4 cases (26.7%), are improved for 0 case, have no effect for 0 case, have 100% effective rate and have unexpected good effect.
The same experiment is carried out on the example 1 and the examples 2 and 3 at the same time, and the same and similar results are obtained, which shows that the product has good quality and stable and reliable curative effect, and are not listed any more.
The experiments show that the invention has scientific and reasonable compatibility, mutual support of the components, safe medication, stable and reliable curative effect and easy production and preparation, is used for treating soft tissue injury, is an innovation of medicaments for treating soft tissue injury, and has obvious economic and social benefits.
Claims (4)
1. The Huojindan essential oil for treating soft tissue injury by external use is characterized by comprising the following components: 2-4mL of datura flower essential oil, 2-4mL of tree peony bark essential oil, 2-4mL of giant knotweed essential oil, 2-4mL of pubescent angelica root essential oil, 2-4mL of frankincense essential oil, 2-4mL of immature bitter orange essential oil, 1.5-2.5mL of campsis grandiflora essential oil, 1.5-2.5mL of garden balsam stem essential oil, 1.5-2.5g of borneol and 1.5-2.5g of camphor, and uniformly mixing, wherein:
the flos Daturae Metelis essential oil is prepared by pulverizing flos Daturae Metelis into coarse powder passing through a 10-20 mesh sieve and supercritical CO2Fluid extraction is carried out, the weight volume ratio of liquid to material is 1: 10-20, the weight volume ratio refers to the weight volume of solid in g, the weight volume of liquid in mL, and the extraction temperatureExtracting at 42-50 ℃ and under 20-25 MPa, separating at 50-60 ℃ and under 4.5-5.5 MPa for 1.5-2.5 h to obtain flos Daturae Metelis essential oil;
the preparation methods of the tree peony bark essential oil, the giant knotweed essential oil, the pubescent angelica essential oil, the frankincense essential oil, the immature bitter orange essential oil, the campsis grandiflora essential oil and the garden balsam stem essential oil are the same as those of the datura flower essential oil.
2. The Huojindan essential oil for external use for treating soft tissue injury according to claim 1, which is prepared from the following components: 3mL of datura flower essential oil, 3mL of tree peony bark essential oil, 3mL of giant knotweed essential oil, 3mL of pubescent angelica root essential oil, 3mL of frankincense essential oil, 3mL of immature bitter orange essential oil, 2mL of campsis grandiflora essential oil, 2mL of garden balsam stem essential oil, 2g of borneol and 2g of camphor, and uniformly mixing.
3. The Huojindan essential oil for external use for treating soft tissue injury according to claim 1, which is prepared from the following components: 2.5mL of datura flower essential oil, 3.5mL of tree peony bark essential oil, 2.5mL of giant knotweed essential oil, 3.5mL of pubescent angelica root essential oil, 2.5mL of frankincense essential oil, 3.5mL of immature bitter orange essential oil, 1.7mL of campsis grandiflora essential oil, 2.3mL of garden balsam stem essential oil, 1.7g of borneol and 2.3g of camphor.
4. The Huojindan essential oil for external use for treating soft tissue injury according to claim 1, which is prepared from the following components: 3.5mL of datura flower essential oil, 2.5mL of tree peony bark essential oil, 3.5mL of giant knotweed essential oil, 2.5mL of pubescent angelica root essential oil, 3.5mL of frankincense essential oil, 2.5mL of immature bitter orange essential oil, 2.3mL of campsis grandiflora essential oil, 1.7mL of garden balsam stem essential oil, 2.3g of borneol and 1.7g of camphor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911306164.6A CN111000925A (en) | 2019-12-18 | 2019-12-18 | External application Huojindan essential oil for treating soft tissue injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911306164.6A CN111000925A (en) | 2019-12-18 | 2019-12-18 | External application Huojindan essential oil for treating soft tissue injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111000925A true CN111000925A (en) | 2020-04-14 |
Family
ID=70116378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911306164.6A Pending CN111000925A (en) | 2019-12-18 | 2019-12-18 | External application Huojindan essential oil for treating soft tissue injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111000925A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1090196A (en) * | 1993-10-30 | 1994-08-03 | 陈显志 | Liquid for curing bone fracture |
| CN104623073A (en) * | 2013-11-07 | 2015-05-20 | 魏世年 | Preparation method of traditional Chinese medicinal tincture for treating sprain |
| CN109125474A (en) * | 2018-10-15 | 2019-01-04 | 河南中医药大学 | A kind of silver yellow ginseng essential oil for treating solar dermatitis |
-
2019
- 2019-12-18 CN CN201911306164.6A patent/CN111000925A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1090196A (en) * | 1993-10-30 | 1994-08-03 | 陈显志 | Liquid for curing bone fracture |
| CN104623073A (en) * | 2013-11-07 | 2015-05-20 | 魏世年 | Preparation method of traditional Chinese medicinal tincture for treating sprain |
| CN109125474A (en) * | 2018-10-15 | 2019-01-04 | 河南中医药大学 | A kind of silver yellow ginseng essential oil for treating solar dermatitis |
Non-Patent Citations (1)
| Title |
|---|
| 梁晓夏，等: "正骨祛痛酊治疗急性软组织损伤的疗效观察", 《中国药房》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102579583B (en) | External patch for treating injury of tendons | |
| CN102772712A (en) | Traditional Chinese medicine composition for treating heat-toxicity, flourishing and blood stasis type diabetic foot | |
| CN109432269A (en) | A kind of Chinese medicine composition and preparation method, purposes | |
| CN110075274B (en) | A pharmaceutical composition for treating or preventing nerve injury | |
| CN110558561A (en) | Compound composition with effect of promoting bone joint health and application thereof | |
| CN105663469A (en) | Chinese medicine external application agent for treating bone fractures and nursing method | |
| CN111000925A (en) | External application Huojindan essential oil for treating soft tissue injury | |
| CN103751309A (en) | Traditional Chinese medicine external preparation for treating intercostal neuralgia and preparation method thereof | |
| CN1186067C (en) | Medicine for curing acute injury of muscle and tendon and its preparation method | |
| CN115177690B (en) | Traditional Chinese medicine composition for treating osteoarthritis and preparation method thereof | |
| CN103735676B (en) | A kind of compound Chinese medicinal preparation for the treatment of traumatic injury and its preparation method and application | |
| CN114028483B (en) | Pharmaceutical composition and preparation for treating chronic soft tissue injury | |
| CN115252742B (en) | A Chinese medicinal oral preparation for treating traumatic injury and fracture | |
| CN102406924B (en) | Medicine composition for treating cerebrovascular and cardiovascular diseases as well as preparation method and application thereof | |
| CN109806321B (en) | A Chinese medicinal composition, its preparation method and application in preparing medicine for treating trauma | |
| CN1259949C (en) | Capsule for treating wound | |
| CN1201791C (en) | Wind dispelling and pain relieving ointment | |
| CN1114420C (en) | Medicine for treating intractable ischias and chronic lumbocrural pain and its preparing process | |
| CN105232642A (en) | Traditional Chinese medicine combination capable of promoting fracture healing | |
| CN1090196A (en) | Liquid for curing bone fracture | |
| CN104435136A (en) | Pharmaceutical composition for accelerating fracture healing and preparation method thereof | |
| CN111671819A (en) | Pure traditional Chinese medicine transdermal liniment for treating hemiplegia and preparation method thereof | |
| CN118178509A (en) | Traditional Chinese medicine emulsifiable paste for treating rheumatalgia and preparation method thereof | |
| CN103690644A (en) | Traditional Chinese medicine preparation for promoting fracture rehabilitation | |
| CN111529667A (en) | Traditional Chinese medicine composition for treating lumbar intervertebral disc protrusion and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200414 |